INS and type 2 diabetes mellitus: LY2405319, another FGF21 analog, was found to improve lipid levels, lipoprotein profile, body weight, fasting insulin, and adiponectin levels in obese patients with type 2 diabetes in a randomized, placebo-controlled, double-blind clinical trial (52).